查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092035

藥物釋放型支架市場－2026-2032年全球市場預測

Drug Eluting Stent Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物釋放型支架市場將成長至 112.2 億美元，複合年成長率為 8.46%。

主要市場統計數據
基準年 2025 63.5億美元
預計年份：2026年 67.5億美元
預測年份：2032年 112.2億美元
複合年成長率 (%) 8.46%

藥物釋放型支架可改善冠狀動脈介入治療的效果。

藥物釋放型支架市場是現代心臟介入醫學的核心，它透過將機械血管支撐結構與局部可控釋放抗增殖藥物相結合，為冠狀動脈疾病患者的經皮冠狀動脈介入治療（PCI）提供支持。與早期的裸金屬支架相比，現代藥物釋放型支架旨在提高長期血管通暢性，同時減少新生內膜增生和血管再阻塞。全球冠狀動脈疾病負擔、人口老化、糖尿病盛行率、高血壓、肥胖和吸菸等因素，以及微創心血管手術的普及，都影響藥物洗脫支架的臨床應用。目前的創新重點包括更細的支架梁、生物相容性或可生物分解的聚合物、改進的藥物釋放動力學、增強在複雜病變中的植入性，以及適用於高風險解剖和臨床特徵的支架平台。監管審查仍然嚴格，因為醫療設備安全、延遲血栓症形成的風險、雙重抗血小板治療的必要性以及實際療效仍然是醫院、醫生、保險公司和衛生部門關注的關鍵因素。

一項變革性的變革，重新定義了藥物釋放型支架的引入方式。

在藥物釋放型支架領域，一場結構性變革正在發生，從以器械為中心的創新轉向以實證醫學為基礎、以患者為中心的冠狀動脈治療。介入性心臟病學計畫越來越關注複雜經皮冠狀動脈介入治療（PCI）的療效，包括多支血管病變、左主幹病變、分叉病變、鈣化血管、長病變、糖尿病相關冠狀動脈疾病以及高出血風險患者。這種轉變推動了對兼具徑向強度、柔軟性、低穿透性、適應性和可預測藥物釋放的支架系統的需求。醫療系統也更重視真實世界數據、上市後監測和基於註冊登記的性能監測，以檢驗對照試驗以外的療效。隨著血管內影像、生理觀察、病灶準備技術和最佳化抗血小板治療與藥物釋放型支架置入術的更緊密結合，手術標準也在不斷發展。同時，報銷機制和基於價值的採購正在推動設備選擇不僅基於產品功能，而且基於可衡量的臨床益處、整體治療效率和減少重組手術。

人工智慧對支架創新技術的累積影響

人工智慧正對藥物釋放型支架生態系統產生累積影響，涵蓋從研發設計到臨床工作流程和術後監測的各個環節。在器械研發方面，人工智慧驅動的建模有助於最佳化支架形態、評估聚合物性能、進行血流動力學模擬，並預測各種血管條件下與血管再阻塞和血栓症相關的風險因素。在臨床實踐中，機器學習工具正被擴大用於改善冠狀動脈影像的解讀、量化病灶形態、輔助鈣化評估，並結合血管造影術、血管內超音波、光學同調斷層掃描(OCT) 或電腦斷層掃描 (CT) 資料支援手術方案的發展。人工智慧還可以透過整合合併症、用藥依從性、出血風險、腎功能和先前心血管事件等因素來增強患者分層，從而指導支架選擇和抗血小板治療的決策。在醫療保健系統中，人工智慧驅動的註冊分析和上市後監測能夠更快地識別安全訊號、手術差異和長期預後模式。然而，要實現這一目標，需要檢驗的演算法、透明的臨床證據、與導管室系統的互通性、網路安全措施、減少偏見以及遵守醫療設備軟體法規。

對全球藥物釋放型支架需求的關鍵區域洞察。

亞太地區（包括中國、印度、日本、韓國、澳洲和東南亞）是藥物釋放型支架的重點應用區域，這主要歸因於心血管疾病負擔日益加重、導管室基礎設施不斷完善、醫保覆蓋範圍擴大以及經皮冠狀動脈介入治療的可及性提高。北美地區的特點是擁有先進的心臟介入治療能力、臨床指南的持續有效實施、在複雜病例中廣泛應用血管內影像技術，以及監管機構和保險公司嚴格的證據要求。在拉丁美洲，都市區的心臟護理服務正在不斷擴展，但成本效益、報銷制度的差異以及專科醫生分佈不均仍然影響著治療的可及性。歐洲受益於成熟的循環系統醫療保健網路、活躍的臨床研究以及在不斷發展的醫療設備法規框架下統一的品質標準，而這些標準的採納則受到公共採購規範和國家醫療技術評估的影響。在中東，尤其是在高所得的海灣國家，透過專科心臟中心、醫療旅遊計畫以及對先進導管室基礎設施的投資，三級心臟護理服務的能力正在不斷提升。在非洲，雖然冠狀動脈介入治療的發展主要集中在大都會醫院，但基礎設施差距、勞動力短缺和成本挑戰仍然影響藥物洗脫支架的供應，導致藥物釋放型支架的取得進入了一個新的階段。

影響支架取得和採購的關鍵群體洞察

在東協市場，隨著醫療體系加大對三級心臟護理中心、培訓計畫和更廣泛的心血管篩檢的投入，藥物釋放型支架的使用正在逐步增加；然而，採購政策和自付費用仍然是影響其普及的重要因素。海灣合作理事會國家（GCC）的特點是糖尿病、肥胖和久坐的生活方式導致心血管風險較高，同時這些國家也大力投資於專科醫院和先進的心臟導管介入基礎設施。歐盟維持著高度監管、循證的市場環境，醫療設備的性能、臨床安全性、可追溯性和上市後證據對於市場准入和醫院採購至關重要。在金磚國家，沉重的疾病負擔加上不斷擴大的國內醫療體系，使得價格負擔、本地生產政策、公共部門競標以及都市區醫療資源分配不均等問題成為重要的考量。在七國集團（G7）國家，先進的藥物釋放型支架平台應用普遍成熟，這得益於完善的報銷機制、臨床註冊登記和先進的手術能力。北約成員國與北美和歐洲的先進醫療保健系統有很大的重疊，在這些國家，醫院的準備情況、監管的一致性和供應鏈的韌性對於心血管醫療設備的採購和醫療保健的連續性變得越來越重要。

藥物釋放型支架市場市場動態的關鍵國家洞察

美國在經經皮冠狀動脈介入治療（PCI）領域處於主導，這得益於其專業的冠心病中心、臨床指南的採納以及在評估藥物釋放型支架性能方面廣泛應用真實世界數據（REW）。加拿大優先考慮透過其公共醫療保健系統實現公平的醫療服務獲取，其實施受到省級採購政策、臨床有效性和結果評估的影響。墨西哥正在主要城市擴建介入性心臟病學基礎設施，但公立和私立醫療機構在醫療服務取得上的差異影響了醫療設備的使用。巴西心血管疾病負擔沉重，擁有完善的三級醫療設施，但報銷制度和區域差異影響了先進支架技術的取得。在英國，基於指引的冠心病護理、全國性臨床審計和成本效益評估，支架的應用正在穩步推進。德國是歐洲心臟導管介入治療的領先中心，這得益於其高超的手術技術、完善的醫院基礎設施和嚴格的品質標準。在法國，成熟的心血管護理管道與報銷監管和臨床證據要求相結合。俄羅斯已投資建造心血管中心和急性冠狀動脈症候群網路，但區域准入和採購趨勢仍是重大挑戰。義大利和西班牙擁有成熟的循環系統醫療保健體系，但其應用程度因地區衛生部門預算和臨床實踐而異。中國正透過醫院擴建、醫師訓練、自主研發醫療器材以及龐大的病患群體，迅速提升其冠狀動脈介入治療能力。在印度，受冠狀動脈疾病高發生率、都市區心臟護理服務擴展以及價格敏感型採購趨勢的推動，需求正在不斷成長。日本的特點是技術先進、人口老化以及對安全性和醫療設備品質的高度重視。澳洲在監管完善的醫療保健環境和高度專業化的醫生網路中，堅持循證醫學的應用。韓國兼具高水準的技術準備、先進的醫院以及在臨床實踐中積極應用最新心臟導管介入技術。

藥物釋放型支架領導企業採用的實用建議

產業領導企業應優先開發臨床差異化的藥物釋放型支架平台，以應對複雜病變、高出血風險患者、糖尿病患者以及合併多種疾病的老年患者。產品開發應著重於更細的支架梁、持久的藥物傳遞、最佳化的聚合物生物相容性、可控的藥物釋放型洗脫以及與影像引導和生理引導的經皮冠狀動脈介入治療（PCI）流程的兼容性。實證策略應超越關鍵臨床試驗，涵蓋真實世界臨床註冊研究、長期追蹤研究、次族群分析以及關於血管再阻塞、支架血栓症、目標病變失敗和重組的透明安全性報告。銷售團隊應與醫院評估委員會合作，展現手術效率、生命週期價值、供應可靠性和培訓支援。區域策略，尤其是在新興經濟體，必須體現保險報銷體系、採購體系、當地監理要求和成本效益限制的成熟度。此外，領導者應投資於醫生教育、人工智慧驅動的手術規劃夥伴關係、數位化上市後監測以及供應鏈韌性，以維持導管室網路和整個醫療保健系統的信心。

基於檢驗證據的調查方法

本執行摘要採用系統性的二手調查方法撰寫，重點在於檢驗的臨床、監管和醫療保健系統證據。該方法包括分析同行評審的循環系統文獻、介入性心臟病學指南、關於冠狀動脈疾病和心血管危險因素的公共衛生數據、醫療設備監管文件、醫院技術評估實踐、臨床實驗室結果、註冊登記出版物以及公開的醫療保健基礎設施指標。透過交叉檢驗疾病負擔、手術應用模式、報銷環境、導管室容量、監管預期和就醫障礙，整合了區域、群體和國家層面的見解。本調查方法不涉及市場規模、市場佔有率和預測；而是強調對應用促進因素、技術趨勢、政策影響和臨床實踐演變進行基於證據的定性分析。所有研究結果均從藥物釋放型支架的表現、病患預後、安全監測和醫療保健服務基礎設施狀況等方面進行解讀。

結論：循證創新將決定支架的未來。

藥物釋放型支架仍然是冠狀動脈疾病治療的基礎技術，其重要性持續得到提升，這得益於臨床療效的改善、微創介入治療的趨勢以及全球對心血管護理日益成長的需求。該領域正透過先進材料、精密的藥物傳輸系統、影像引導植入、人工智慧驅動的決策以及對上市後證據日益成長的期望而不斷發展。區域和國家層面的趨勢顯示出廣泛的應用模式。成熟的醫療體系優先考慮證據、安全性和價值，而新興市場則著重於提高可近性、降低成本、改善基礎設施和加強醫師培訓。未來的競爭將取決於能否將臨床差異化與監管合規性、臨床實踐中的績效透明度、與手術流程的整合以及可靠的全球供應鏈相結合。能夠將創新與個人化病患照護、長期安全性和醫療體系價值相協調的相關人員，將在不斷發展的藥物釋放型支架市場中佔據最佳優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：藥物釋放型支架市場：依類型分類

  • 聚合物塗層類型
    • 可生物分解聚合物塗層
    • 耐用聚合物塗層
  • 不含聚合物

第8章：藥物釋放型支架市場：依藥物分類

  • Biolims溶解型
  • Everolimus洗脫型
  • 紫杉醇洗脫型
  • Sirolimus洗脫型

第9章：藥物釋放型支架市場：依材料類型分類

  • 金屬支架
    • 不銹鋼支架
    • 鈷鉻合金支架
  • 生物可吸收支架
    • 以聚合物為基礎的生物可吸收支架
    • 鎂基支架

第10章：藥物釋放型支架市場：依應用領域分類

  • 冠狀動脈疾病
  • 周邊血管疾病

第11章：藥物釋放型支架市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第12章：藥物釋放型支架市場：依分銷管道分類

  • 離線
  • 線上

第13章：藥物釋放型支架市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：藥物釋放型支架市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：藥物釋放型支架市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Acrostak AG
  • Amaranth Medical Inc.
  • B. Braun SE
  • Balton Sp. z oo
  • Biosensors International Group Ltd.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Concept Medical Inc.
  • Elixir Medical Corporation
  • Endocor GmbH
  • iVascular SLU
  • JW Medical Systems
  • Lepu Medical Technology Beijing Co. Ltd.
  • Medinol Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • Relisys Medical Devices Ltd.
  • Sahajanand Medical Technologies Limited
  • Sino Medical Sciences Technology Inc.
  • STENTYS SA
  • Terumo Corporation
  • Translumina GmbH
Product Code: MRR-807A20B5CCC6

The Drug Eluting Stent Market is projected to grow by USD 11.22 billion at a CAGR of 8.46% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.35 billion
Estimated Year [2026] USD 6.75 billion
Forecast Year [2032] USD 11.22 billion
CAGR (%) 8.46%

Drug Eluting Stents Advance Coronary Intervention Outcomes

The drug eluting stent market is central to modern interventional cardiology, supporting percutaneous coronary intervention for patients with coronary artery disease by combining mechanical vessel scaffolding with controlled local delivery of antiproliferative drugs. Compared with early bare-metal stents, contemporary drug eluting stents are designed to reduce neointimal hyperplasia and restenosis while improving long-term vessel patency. Clinical adoption is being shaped by the global burden of ischemic heart disease, aging populations, diabetes prevalence, hypertension, obesity, smoking exposure, and the expanding use of minimally invasive cardiac procedures. Current innovation priorities include thinner struts, biocompatible or biodegradable polymers, improved drug-release kinetics, enhanced deliverability in complex lesions, and stent platforms suitable for high-risk anatomical and clinical profiles. Regulatory scrutiny remains rigorous because device safety, late thrombosis risk, dual antiplatelet therapy requirements, and real-world performance remain decisive factors for hospitals, physicians, payers, and health authorities.

Transformative Shifts Redefining Drug Eluting Stent Adoption

The drug eluting stent landscape is undergoing a structural shift from device-centric innovation toward evidence-led, patient-specific coronary care. Interventional cardiology programs are increasingly prioritizing outcomes in complex percutaneous coronary intervention, including multivessel disease, left main lesions, bifurcations, calcified vessels, long lesions, diabetes-associated coronary disease, and patients at high bleeding risk. This shift is increasing demand for stent systems that combine radial strength, flexibility, low crossing profile, conformability, and predictable drug release. Health systems are also placing greater emphasis on real-world evidence, post-market surveillance, and registry-based performance monitoring to validate outcomes beyond controlled trials. Procedural standards are changing as intravascular imaging, physiology-guided decision-making, lesion preparation technologies, and optimized antiplatelet strategies become more integrated with drug eluting stent implantation. At the same time, reimbursement frameworks and value-based procurement are encouraging device selection based on measurable clinical benefit, total episode-of-care efficiency, and reduced repeat revascularization rather than product features alone.

Cumulative Impact of Artificial Intelligence on Stent Innovation

Artificial intelligence is cumulatively influencing the drug eluting stent ecosystem across discovery, design, clinical workflow, and post-procedure monitoring. In device development, AI-enabled modeling can support stent geometry optimization, polymer behavior assessment, hemodynamic simulation, and prediction of restenosis or thrombosis-related risk factors under varied vessel conditions. In clinical practice, machine learning tools are increasingly being explored to improve coronary image interpretation, quantify lesion morphology, support calcium assessment, and assist procedural planning when combined with angiography, intravascular ultrasound, optical coherence tomography, or computed tomography data. AI can also strengthen patient stratification by integrating comorbidities, medication adherence patterns, bleeding risk, renal function, and prior cardiovascular events to guide stent selection and antiplatelet therapy decisions. For healthcare systems, AI-supported registry analytics and post-market surveillance can identify safety signals, procedural variation, and long-term outcome patterns more rapidly. However, adoption depends on validated algorithms, transparent clinical evidence, interoperability with cath lab systems, cybersecurity safeguards, bias mitigation, and compliance with medical device software regulations.

Key Regional Insights Across Global Drug Eluting Stent Demand

Asia-Pacific is a high-priority region for drug eluting stents due to rising cardiovascular disease burden, expanding catheterization laboratory infrastructure, growing insurance coverage, and increasing access to percutaneous coronary intervention in China, India, Japan, South Korea, Australia, and Southeast Asian markets. North America remains defined by advanced interventional cardiology capabilities, robust clinical guideline implementation, high use of intravascular imaging in complex cases, and stringent evidence expectations from regulators and payers. Latin America is progressing through broader access to cardiac care in urban centers, although affordability, reimbursement variation, and unequal specialist distribution continue to influence procedure access. Europe benefits from mature cardiology networks, strong clinical research activity, and harmonized quality expectations under evolving medical device regulations, with adoption shaped by public procurement discipline and national health technology assessment. The Middle East is expanding tertiary cardiac care capacity through specialized heart centers, medical tourism initiatives, and investments in advanced cath lab infrastructure, particularly in high-income Gulf economies. Africa presents an emerging access landscape where coronary intervention growth is concentrated in major metropolitan hospitals, while infrastructure gaps, workforce constraints, and affordability challenges continue to affect drug eluting stent availability.

Key Group Insights Shaping Stent Access and Procurement

ASEAN markets are experiencing gradual growth in drug eluting stent utilization as healthcare systems invest in tertiary cardiac centers, training programs, and broader cardiovascular screening, although procurement policies and out-of-pocket costs remain important adoption factors. The GCC is distinguished by high cardiovascular risk linked to diabetes, obesity, and sedentary lifestyles, alongside strong investment in specialty hospitals and advanced interventional cardiology infrastructure. The European Union maintains a highly regulated and evidence-driven environment where device performance, clinical safety, traceability, and post-market evidence are critical to market access and hospital procurement. BRICS economies combine substantial disease burden with expanding domestic healthcare capacity, making affordability, local manufacturing policy, public-sector tendering, and urban-rural access disparities important considerations. G7 countries generally demonstrate mature adoption of contemporary drug eluting stent platforms, supported by established reimbursement systems, clinical registries, and advanced procedural capabilities. NATO member countries overlap significantly with developed healthcare systems in North America and Europe, where hospital readiness, regulatory alignment, and supply chain resilience are increasingly relevant to cardiovascular device procurement and continuity of care.

Key Country Insights for Drug Eluting Stent Market Dynamics

The United States leads in advanced percutaneous coronary intervention practice, supported by specialized cardiac centers, clinical guideline adoption, and extensive use of real-world evidence in evaluating drug eluting stent performance. Canada emphasizes equitable access through publicly funded healthcare systems, with adoption shaped by provincial procurement, clinical appropriateness, and outcomes-based evaluation. Mexico is expanding interventional cardiology capacity in major cities, while access differences between public and private care settings influence device utilization. Brazil has a large cardiovascular disease burden and established tertiary hospitals, with reimbursement structures and regional disparities affecting access to advanced stent technologies. The United Kingdom relies on guideline-driven coronary care, national clinical audits, and cost-effectiveness assessments to guide adoption. Germany is a major European center for interventional cardiology, supported by high procedural capability, strong hospital infrastructure, and rigorous quality standards. France combines established cardiovascular care pathways with reimbursement oversight and clinical evidence requirements. Russia has invested in cardiovascular centers and acute coronary syndrome networks, though regional access and procurement dynamics remain important. Italy and Spain have mature cardiology systems, with adoption shaped by regional health authority budgets and clinical practice variation. China is rapidly advancing coronary intervention capacity through hospital expansion, physician training, domestic device development, and large patient volumes. India shows rising demand driven by coronary artery disease prevalence, urban cardiac care expansion, and affordability-sensitive purchasing. Japan is characterized by high procedural sophistication, aging demographics, and strong emphasis on safety and device quality. Australia maintains evidence-led adoption within a regulated healthcare environment and advanced specialist networks. South Korea combines high technology readiness, sophisticated hospitals, and strong clinical adoption of contemporary interventional cardiology techniques.

Actionable Recommendations for Drug Eluting Stent Leaders

Industry leaders should prioritize clinically differentiated drug eluting stent platforms that address complex lesions, high bleeding risk patients, diabetic populations, and aging patients with multiple comorbidities. Product development should focus on thinner struts, durable deliverability, optimized polymer biocompatibility, controlled drug elution, and compatibility with imaging-guided and physiology-guided PCI workflows. Evidence strategies should extend beyond pivotal trials to include real-world registries, longer-term follow-up, subgroup analyses, and transparent safety reporting on restenosis, stent thrombosis, target lesion failure, and repeat revascularization. Commercial teams should align with hospital value committees by demonstrating procedural efficiency, lifecycle value, supply reliability, and training support. Regional strategies must reflect reimbursement maturity, procurement systems, local regulatory requirements, and affordability constraints, particularly in emerging economies. Leaders should also invest in physician education, AI-enabled procedural planning partnerships, digital post-market surveillance, and supply chain resilience to maintain trust across cath lab networks and healthcare systems.

Research Methodology Grounded in Verified Evidence

This executive summary is developed using a structured secondary research methodology focused on verified clinical, regulatory, and healthcare system evidence. The approach includes analysis of peer-reviewed cardiology literature, interventional cardiology guidelines, public health data on coronary artery disease and cardiovascular risk factors, medical device regulatory documentation, hospital technology assessment practices, clinical trial findings, registry publications, and publicly available healthcare infrastructure indicators. Regional, group, and country-level insights are synthesized through cross-validation of disease burden, procedural adoption patterns, reimbursement context, cath lab capacity, regulatory expectations, and access barriers. The methodology excludes market sizing, market share, and forecasting and instead emphasizes evidence-backed qualitative analysis of adoption drivers, technology trends, policy influences, and clinical practice evolution. All findings are interpreted through the lens of drug eluting stent performance, patient outcomes, safety monitoring, and healthcare delivery readiness.

Conclusion: Evidence-Led Innovation Defines the Future of Stents

Drug eluting stents remain a foundational technology in the treatment of coronary artery disease, with continued relevance driven by improved clinical outcomes, minimally invasive intervention trends, and growing cardiovascular care needs worldwide. The sector is evolving through advanced materials, refined drug-release systems, imaging-guided implantation, AI-supported decision-making, and stronger post-market evidence expectations. Regional and country dynamics show that adoption is not uniform: mature healthcare systems emphasize evidence, safety, and value, while emerging markets focus on access expansion, affordability, infrastructure development, and physician training. Future competitive strength will depend on the ability to combine clinical differentiation with regulatory compliance, real-world performance transparency, procedural workflow integration, and reliable global supply. Stakeholders that align innovation with patient-specific care, long-term safety, and healthcare system value will be best positioned in the evolving drug eluting stent landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Eluting Stent Market, by Type

  • 7.1. Introduction
  • 7.2. Polymer Coated
    • 7.2.1. Biodegradable Polymer Coated
    • 7.2.2. Durable Polymer Coated
  • 7.3. Polymer Free

8. Drug Eluting Stent Market, by Drug

  • 8.1. Introduction
  • 8.2. Biolimus Eluting
  • 8.3. Everolimus Eluting
  • 8.4. Paclitaxel Eluting
  • 8.5. Sirolimus Eluting

9. Drug Eluting Stent Market, by Material Type

  • 9.1. Introduction
  • 9.2. Metallic Stents
    • 9.2.1. Stainless Steel Stents
    • 9.2.2. Cobalt Chromium Stents
  • 9.3. Bioresorbable Stents
    • 9.3.1. Polymer Based Bioresorbable Stents
    • 9.3.2. Magnesium Based Stents

10. Drug Eluting Stent Market, by Application

  • 10.1. Introduction
  • 10.2. Coronary Artery Disease
  • 10.3. Peripheral Vascular Disease

11. Drug Eluting Stent Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Hospitals

12. Drug Eluting Stent Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline
  • 12.3. Online

13. Drug Eluting Stent Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Drug Eluting Stent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Eluting Stent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Acrostak AG
  • 17.3. Amaranth Medical Inc.
  • 17.4. B. Braun SE
  • 17.5. Balton Sp. z o.o.
  • 17.6. Biosensors International Group Ltd.
  • 17.7. BIOTRONIK SE & Co. KG
  • 17.8. Boston Scientific Corporation
  • 17.9. Cardionovum GmbH
  • 17.10. Concept Medical Inc.
  • 17.11. Elixir Medical Corporation
  • 17.12. Endocor GmbH
  • 17.13. iVascular S.L.U.
  • 17.14. JW Medical Systems
  • 17.15. Lepu Medical Technology Beijing Co. Ltd.
  • 17.16. Medinol Ltd.
  • 17.17. Medtronic plc
  • 17.18. Meril Life Sciences Pvt. Ltd.
  • 17.19. MicroPort Scientific Corporation
  • 17.20. OrbusNeich Medical Company Limited
  • 17.21. Relisys Medical Devices Ltd.
  • 17.22. Sahajanand Medical Technologies Limited
  • 17.23. Sino Medical Sciences Technology Inc.
  • 17.24. STENTYS SA
  • 17.25. Terumo Corporation
  • 17.26. Translumina GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG ELUTING STENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DRUG ELUTING STENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DRUG ELUTING STENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DRUG ELUTING STENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG ELUTING STENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POLYMER COATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POLYMER COATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POLYMER COATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIODEGRADABLE POLYMER COATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIODEGRADABLE POLYMER COATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIODEGRADABLE POLYMER COATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DURABLE POLYMER COATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DURABLE POLYMER COATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DURABLE POLYMER COATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POLYMER FREE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POLYMER FREE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POLYMER FREE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLIMUS ELUTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLIMUS ELUTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLIMUS ELUTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EVEROLIMUS ELUTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EVEROLIMUS ELUTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EVEROLIMUS ELUTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PACLITAXEL ELUTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PACLITAXEL ELUTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PACLITAXEL ELUTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SIROLIMUS ELUTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SIROLIMUS ELUTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SIROLIMUS ELUTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL METALLIC STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL METALLIC STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL METALLIC STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STAINLESS STEEL STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STAINLESS STEEL STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STAINLESS STEEL STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COBALT CHROMIUM STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COBALT CHROMIUM STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COBALT CHROMIUM STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIORESORBABLE STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIORESORBABLE STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIORESORBABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POLYMER BASED BIORESORBABLE STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POLYMER BASED BIORESORBABLE STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POLYMER BASED BIORESORBABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MAGNESIUM BASED STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MAGNESIUM BASED STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MAGNESIUM BASED STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PERIPHERAL VASCULAR DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERIPHERAL VASCULAR DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PERIPHERAL VASCULAR DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GCC DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GCC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 144. GCC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 145. GCC DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. GCC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GCC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. G7 DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. G7 DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 174. G7 DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 175. G7 DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 178. G7 DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. NATO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 184. NATO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 185. NATO DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 187. NATO DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 188. NATO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. CANADA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. CANADA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CANADA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 205. CANADA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. MEXICO DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. MEXICO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MEXICO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. SPAIN DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 306. INDIA DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. INDIA DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 308. INDIA DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 309. INDIA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 310. INDIA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. INDIA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 316. JAPAN DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 325. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 326. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 328. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. AUSTRALIA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 332. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 335. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 336. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, BY METALLIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 338. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 339. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 340. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 341. SOUTH KOREA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 342. GLOBAL DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 343. GLOBAL DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025